![]() |
Volumn 9, Issue 8, 2000, Pages 1723-1729
|
Cationic antimicrobial peptides: Towards clinical applications
|
Author keywords
Anti endotoxic; Antibiotics; Antifungal; Antimicrobial peptides; Catheter associated infections; Oral mucositis; Protegrins; Topical
|
Indexed keywords
AMINO ACID;
ANTIINFECTIVE AGENT;
CATION;
COLISTIN;
CP 28;
DIAMINOBUTYRIC ACID;
GRAMICIDIN S;
HISTAT GEL;
HISTATIN;
HISTAWASH;
IB 367;
INDOLICIDIN;
MARGAININ IJ;
MBI 226;
MBI 28;
MBI 594AN;
MYCOPREX;
NATURAL PRODUCT;
NISALPIN;
NISIN;
OFLOXACIN;
PEPTIDE;
PEXIGANAN ACETATE;
PLACEBO;
POLYMYXIN B;
POLYPHEMUSIN;
POLYSPORIN;
PR 39;
PROTEGRIN;
PSEUDOMONIC ACID;
RECOMBINANT BACTERICIDAL PERMEABILITY INCREASING PROTEIN;
RECOMBINANT PROTEIN;
SARALASIN;
UNCLASSIFIED DRUG;
UNINDEXED DRUG;
XMP 366;
ANIMAL EXPERIMENT;
ANIMAL MODEL;
ANIMAL TISSUE;
ANTIFUNGAL ACTIVITY;
ANTIMICROBIAL ACTIVITY;
ANTIMICROBIAL THERAPY;
ANTIVIRAL ACTIVITY;
CENTRAL VENOUS CATHETER;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DRUG ACTIVITY;
DRUG EFFICACY;
HUMAN;
IMMUNITY;
INSTRUMENT STERILIZATION;
MENINGOCOCCEMIA;
MOUTH MUCOSA;
MUCOSA INFLAMMATION;
NONHUMAN;
PHASE 2 CLINICAL TRIAL;
PHASE 3 CLINICAL TRIAL;
PROTEIN VARIANT;
REVIEW;
SEPTIC SHOCK;
|
EID: 0033871574
PISSN: 13543784
EISSN: None
Source Type: Journal
DOI: 10.1517/13543784.9.8.1723 Document Type: Review |
Times cited : (152)
|
References (20)
|